Colesterol remanente, riesgo vascular y prevención de la arteriosclerosis

Pintó, Xavier; Fanlo, Marta; Esteve, Virginia; Millán, Jesús.
Clín. investig. arterioscler. (Ed. impr.) ; 35(4): 206-217, Juli-Agos. 2023. ilus, tab, graf
Artículo en Español | IBECS (España) | ID: ibc-223632

Documentos relacionados

  1. Pemafibrate and other triglyceride-lowering therapies to reduce risk of cardiovascular and metabolic disease.
  2. New Era of Lipid-Lowering Drugs.
  3. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.
  4. An update on trials of novel lipid-lowering drugs.
  5. The effect of lipid-lowering therapy on lipid-related residual risk factors: a prospective study.
  6. Remnant cholesterol as a new lipid-lowering target to reduce cardiovascular events.
  7. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
  8. Pharmacotherapy of the Lipid-Lowering Drugs: Update on Efficacy and Risk.
  9. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease, the Impact of Available Lipid-Lowering Medications on Lipoprotein(a): An Update on New Therapies.
  10. The dawn of a new era of targeted lipid-lowering therapies.